Farmas USA

A ver que nos dice Dragui hoy!!...

pues si, DARA +16% en pre

rosg +5%

dara me las quite el viernes, cachissss...

notica de AEZS, en el pre estaba con -7% y ahora esta +11%
en esta si estoy

announced that the European Patent Office has granted a patent for the use of the ghrelin agonist, AEZS-130, related to methods and kits for use in relation to the diagnosis of growth hormone deficiency ("GHD") in a human or animal subject. Filed on February 19, 2007, the patent (EP #1984744 B1) titled, "Methods and Kits to Diagnose Growth Hormone Deficiency", was effective as of September 19, 2012, following its announcement in the European Patent Bulletin, and will expire on February 19, 2027. A similar patent has already

Juergen Engel, Ph.D., Aeterna Zentaris President and CEO, commented, "This patent in Europe, along with the one already granted in the U.S., are key elements to ensure the protection of AEZS-130 for the diagnosis of GHD, in the world's two largest markets. We now look forward to filing a New Drug Application in the near future in the U.S. for AEZS-130, which could become the first approved oral diagnostic test for adults with GHD

buenas tardes cowboys!!
Preparados para otra tarde de rodeo????
Qcor

Seguimos con buenas noticias, esta vez para ATRS, parece que finalemnte se a animar :)

Antares Pharma Announces Successful Results from VIBEX MTX Actual Human Use Study

http://finance.yahoo.com/news/antares-pharma-announces-successful-results-110000219.html